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A B S T R A C T
Rett syndrome (RTT) is a progressive neurodevelopmental disorder mainly caused by mutations in the X-linked
MECP2 gene. RTT patients show multisystem disturbances associated with an oxinflammatory status.
Inflammasomes are multi-protein complexes, responsible for host immune responses against pathogen infections
and redox-related cellular stress. Assembly of NLRP3/ASC inflammasome triggers pro-caspase-1 activation, thus,
resulting in IL-1β and IL-18 maturation. However, an aberrant activation of inflammasome system has been
implicated in several human diseases. Our aim was to investigate the possible role of inflammasome in the
chronic subclinical inflammatory condition typical of RTT, by analyzing this complex in basal and lipopoly-
saccharide (LPS)+ATP-stimulated primary fibroblasts, as well as in serum from RTT patients and healthy vo-
lunteers. RTT cells showed increased levels of nuclear p65 and ASC proteins, pro-IL-1β mRNA, and NLRP3/ASC
interaction in basal condition, without any further response upon the LPS + ATP stimuli. Moreover, augmented
levels of circulating ASC and IL-18 proteins were found in serum of RTT patients, which are likely able to amplify
the inflammatory response. Taken together, our findings suggest that RTT patients exhibited a challenged in-
flammasome machinery at cellular and systemic level, which may contribute to the subclinical inflammatory
state feedback observed in this pathology.
1. Introduction
Rett syndrome (RTT; OMIM identifier #312750), first described by
the physician Andreas Rett [1], is a severe neurodevelopmental dis-
order, predominantly affecting females (approx. 1 per 10,000 live
births) [2]. In 90–95% of patients diagnosed with RTT, the disorder is
due to de novo loss-of-function mutations in the X-linked MECP2 gene,
which encodes methyl-CpG binding protein 2 [3].
After 6-18-months of apparently normal development [4], RTT
leads to both developmental regression, involving loss of hand skills,
motor skills and speech, and a number of co-morbidities, including
breathing disturbances, seizures, gastro-intestinal complications, and
scoliosis [5], allowing to define RTT as a ‘spectrum disorder’. Today,
the complete pathogenic mechanisms linking MECP2 dysfunction to
RTT symptoms are still not clear.
In the last decade, a growing body of evidence supported the idea
that an OxInflammation condition, observed in brain and peripheral
compartments of both RTT patients and animal models, could be in-
volved in RTT pathophysiology [6]. This condition in RTT is due to the
concomitant dysregulation of redox and immune homeostasis and
characterized by a subclinical inflammatory status coupled with an
increased production of oxidant species and a perturbed defense re-
sponse [6–9]. Based on recent findings, cytosolic molecular complexes
termed inflammasomes have emerged as central mediators in the
crosstalk between redox imbalance and inflammation associated with a
wide range of diseases [10]. The assembly of inflammasomes occurs
following the recognition of multiple diverse endogenous and exo-
genous signals such as “pathogen-associated” or “danger-associated
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molecular patterns” (PAMPs or DAMPs) by a cytosolic subset of “pat-
tern recognition receptors” (PRRs), named “nucleotide-binding domain
and leucine-rich repeat-containing (NLR) proteins” [11]. The activation
of these intracellular sensors such as NLRP3, the most widely studied
member among them, triggers the oligomerization and the recruitment
of the adaptor protein ASC, which in turn is able to recruit the effector
protein pro-caspase 1 [12]. The proximity-induced pro-caspase 1 auto-
cleavage leads to the generation of the catalytically active caspase 1
(CASP1), which prompts the downstream responses, consisting of the
conversion of both pro-IL-1β and pro-IL-18 to their biologically active
forms, and/or the proteolytic action of gasdermin D (GSDMD). This
latter promotes the release of GSDMD N-terminal fragments that oli-
gomerize into ring-shaped structures in membranes. GSDMD pores
allow cells to release passively their cytoplasmic content in a size-de-
pendent manner (i.e., cytokines like IL-1β) [13] or drive cells towards
pyroptotic death [11]. Besides its involvement in innate immune re-
sponses, NLRP3 inflammasome has been demonstrated to have a role in
a wide range of inflammatory diseases, cancer, metabolic and auto-
immune disorders, and aging [14–19]. The inflammasome pathway is
implicated even in the neuroinflammation observed in neurodegen-
erative disorders, like multiple sclerosis, Alzheimer's and Parkinson's
disease [20,21] and in neurodevelopmental pathologies, like autistic
spectrum disorders (ASDs) [22].
Since the inflammasome pathway could contribute to the char-
acteristic OxInflammatory status of RTT, this work was aimed at in-
vestigating the activation state of the inflammasome in fibroblasts and
serum samples from RTT patients. We revealed that a deregulated ac-
tivation of inflammasome pathway occurs in RTT, as proved by the
increased constitutive levels of inflammasome components in patient-
derived serum and fibroblast cell lines and by the inability of RTT cells
to activate properly this pathway after further pro-inflammatory chal-
lenges.
2. Materials and methods
2.1. Antibodies
Cell Signaling Technology, Inc. (Danvers, MA, USA) supplied the
following antibodies: anti-nuclear factor κ-light-chain-enhancer of ac-
tivated B cells (NF-κB) p65 subunit antibody (cat. 8242; dil. 1:1,000);
anti-NACHT, LRR and PYD domains-containing protein 3 (NLRP3) an-
tibody (cat. 13158; dil. for WB 1:500 and for IF 1:100); anti-caspase 1
(CASP1) antibody (cat. 2225; dil. 1:1,000), anti-cleaved-IL-1β (cat.
83186; dil. 1:100); anti-glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) (cat. 5174; dil. 1:5,000); anti-histone deacetylase 1 (HDAC1)
antibody (cat. 8242; dil. 1:1,000), and peroxidase-conjugated anti-
rabbit secondary antibody (cat. 7074; dil. 1:10,000). Santa Cruz
Biotechnology, Inc. (Santa Cruz, CA) provided the anti-apoptosis-asso-
ciated speck-like protein containing CARD (ASC) (cat. sc-271054; dil.
for WB 1:800 and for IF 1:200) antibody. Both AlexaFluorTM 488 goat
anti-rabbit IgG (H + L) (cat. A-11008; dil. 1:1,000) and AlexaFluorTM
568 goat anti-mouse IgG (H+ L) (cat. A-11004; dil. 1:1,000) antibodies
were provided by Thermo Fisher Scientific (Waltham, MA, USA). The
peroxidase-conjugated anti-mouse secondary antibody (cat. 170–6515;
dil. 1:10,000) was supplied by Bio-Rad Laboratories (Hercules, CA,
USA).
2.2. Study approval
Female patients with classical RTT and healthy sex- and age-mat-
ched controls were enrolled for the study. All patients were admitted to
the Child Neuropsychiatry Unit of the University Hospital of Siena
(Siena, Italy). Diagnosis and inclusion/exclusion criteria of RTT were
set in agreement with revised RTT nomenclature consensus [4]. The
study was conducted in accordance with the Code of Ethics of the World
Medical Association (Declaration of Helsinki), and the protocol was
approved by the Ethics Committee of Institutional Review Board of
University Hospital, Azienda Ospedaliera Universitaria Senese (AOUS),
Siena, Italy. A written form of the informed consents was signed from
either the parents or the legal tutors of the participants.
2.3. Human fibroblasts culture
Skin biopsies from healthy donors (CTR; N=6) were taken during
health checks or by donations, while skin biopsies from RTT patients
(N= 6; age: 20 ± 3.8, expressed as mean ± SD) were obtained
during the periodic clinical checks-up. Human skin fibroblasts were
isolated by 3-mm skin punch biopsy, as previously described [23].
Before the experimental procedure, fibroblasts were stained for Vi-
mentin and checked for mycoplasma contamination. Cells were cul-
tured with DMEM medium, containing 10% (v/v) fetal bovine serum
(cat. 10-014-CV and cat. 35-011-CV, respectively, Corning, New York,
NY, USA), antibiotics (100 IU/ml penicillin, 100mg/ml streptomycin)
(cat. 30-002-CI; Corning) and incubated in humidified atmosphere (5%
CO2) at 37 °C. All experiments were performed by using fibroblasts
between the third and fifth passage in vitro.
2.4. Cell treatment with LPS and ATP
CTR and RTT fibroblasts were seeded (5,000 cells/cm2) in complete
medium and after 48 h, cells were starved with 1% FBS-containing
medium for 15 h to minimize cell proliferation. Cells were then in-
cubated with or without 100 μg/ml lipopolysaccharide (LPS, dissolved
in water), for 6 h in 1% FBS-supplemented medium and with 5mM
adenosine triphosphate (ATP, dissolved in water) for additional 30min
(cat. L2630 and cat. A6419, respectively, Sigma-Aldrich, St. Louis, MO,
USA). The LPS concentration was calculated based on the evaluation of
NLRP3 gene expression, in response to different concentrations (0, 10,
50, 100 and 200 μg/ml for 6 h), while the ATP treatment was estab-
lished based on literature papers [24,25]. The chosen concentration of
LPS (100 μg/ml) induced an inflammasome-related response and no cell
death was observed (Supplementary Fig. S1).
2.5. Western immunoblot analysis
Fibroblasts were lysed in RIPA buffer (cat. J62524, Alfa Aesar,
Tewksbury, MA, USA), supplemented with 1% (v/v) protease inhibitors
and 1% (v/v) phosphatase inhibitors (cat. 78430 and cat. 1862495,
respectively, Thermo Fisher Scientific, Waltham, MA, USA). After three
freezing-thawing cycles, cell lysates were centrifuged at 17,000×g for
15min at 4 °C, and supernatants were used for the evaluation of total
protein concentration, by using the Quick Start™ Bradford Protein
Assay Kit (cat. 5000201, Bio-rad Laboratories) and bovine serum al-
bumin (BSA) as standard. Samples were denatured and run in triplicates
on 10–15% polyacrylamide gels, as previously reported [26]. Proteins
were transferred from polyacrylamide gels onto polyvinylidene di-
fluoride (PVDF) membranes by electrophoretic transfer. Non-specific
binding sites were blocked at room temperature for 1 h with 5% (w/v)
Blotting-Grade Blocker (cat. 170–6404, Bio-Rad Laboratories), in Tris-
buffer saline containing 0.1% (v/v) Tween-20 (cat. P5927, Sigma–Al-
drich) (TBS-T). Membranes were first incubated overnight with primary
antibodies-containing TBS-T (see the antibodies section), and then with
anti-rabbit or anti-mouse peroxidase-conjugated secondary antibodies
diluted in TBS-T for 2 h at room temperature (see the antibodies sec-
tion). The protein bands were detected by using Clarity™ Western ECL
Substrate Kit (cat. 1705060, Bio-Rad Laboratories) and ChemiDoc™ MP
Imaging System hardware and software (Bio-Rad Laboratories). Images
of bands were analyzed by the Nonlinear Dynamics TotalLab software
(TotalLab Ltd, Newcastle upon Tyne, UK). Data were normalized
against HDAC1 or GAPDH, depending on nuclear or cytosolic/total
proteins analyzed, and results were given as arbitrary units.
A. Pecorelli, et al. Redox Biology 28 (2020) 101334
2
2.6. Subcellular protein fractionation
Nuclear and cytoplasmic protein fractions were prepared by using
the Nuclear Extraction Kit (cat. 2900, Merck Millipore, Burlington, MA,
USA). Briefly, cells were washed with PBS and then were lysed with
Cytoplasmic Lysis Buffer, containing 0.5mM dithiothreitol (DTT) and
0.1% (v/v) protease inhibitor cocktail. After homogenization, the dis-
rupted cell suspension was centrifuged at 8,000×g for 20min at 4 °C,
and the supernatant, containing the cytosolic portion, was recovered.
The remaining pellet was then resuspended in Nuclear Extraction Buffer
supplemented with 0.5 mM DTT and 0.1% (v/v) protease inhibitor
cocktail and homogenized. The resulting nuclear suspension was cen-
trifuged at 16,000×g for 5min at 4 °C and the supernatant, containing
the nuclear extract, was collected [27]. Total protein concentration was
determined by Bradford analysis (Quick Start™ Bradford Protein Assay
Kit, cat. 5000201, Bio-rad Laboratories).
2.7. RNA extraction and real time RT-PCR analysis
As previously reported [28], total RNA was extracted from fibro-
blasts by using Aurum Total RNA Mini Kit (cat.732–6820, Bio-Rad),
removing genomic contamination by using DNase I, as recommended
by the supplier. RNA (1 μg) was converted into complementary DNA by
using iScript Reverse Transcription kit (cat. 1708841, Bio-Rad). The
obtained cDNA (diluted 1:10) was used for the real time PCR step with
SsoAdvanced Universal SYBR Green Supermix (cat. 172–5271, Bioline,
London, UK) in a LightCycler® 480 Instrument (Roche, Indianapolis, IN,
USA). Primers were synthetized by Sigma-Aldrich (St. Louis, MO, USA):
NLRP3 (forward, 5′-CGGGGCCTCTTTTCAGTTCT-3′; reverse, 5′-CCCC
AACCACAATCTCCGAA-3′) (Primer BLAST, accession number: NM_
004895.4); CASP1 (forward, 5′-CCGTTCCATGGGTGAAGGTA-3′; re-
verse, 5′-TGCCCCTTTCGGAATAACGG-3′) (Primer BLAST, accession
number: NM_033292.4); IL-1β (forward, 5′-CACGATGCACCTGTACGA
TCA-3'; reverse, 5′-GTTGCTCCATATCCTGTCCCT-3′) [58]; GAPDH
(forward, 5′-TGACGCTGGGGCTGGCATTG-3′; reverse, 5′- GGCTGGTG
GTCCAGGGGTCT-3′) [26].
The PCR protocol was set as follows: polymerase activation and
initial denaturation at 95 °C for 30 s, and 40 cycles of 95 °C for 15 s and
60 °C for 60 s. In order to check the presence of possible co-amplified
undesired targets, melt-curve analysis was performed for all primer
pairs (65 °C–95 °C, 0.5 °C increment, 2 s/step). Quantitative relative
gene expression was calculated by using the 2−ΔΔCt method [29], using
GAPDH as the reference mRNA and one of the controls as the internal
calibrator. Each sample was processed by analyzing three replicates.
2.8. Immunofluorescence analysis
Fibroblasts were seeded (5,000 cells/cm2) and grown on coverslips
in complete medium. CTR and RTT cells were starved and treated with
LPS + ATP, as described in the “Cell treatment with LPS and ATP” sub-
section. As previously reported [23], cells were washed twice with D-
phosphate buffered saline (PBS), then fixed in 10% (w/v) neutral buf-
fered formalin solution for 10min, and permeabilized in PBS containing
0.25% (v/v) Triton X-100 for 10min at 4 °C. Non-specific binding sites
were blocked with 3% (w/v) BSA in PBS for 30min. Cells were then
incubated with primary antibodies that were diluted in PBS containing
0.5% (w/v) BSA at 4 °C overnight (see the “Antibodies” section for in-
formation about dilutions). After three washes with PBS, cells were
incubated with AlexaFluor 488 or AlexaFluor 568 antibodies-con-
taining PBS at 4 °C for 1 h (see the “Antibodies” section for information
about dilutions). After five washes with PBS, cells were incubated with
a solution of 4′,6-diamidino-2-phenylindole (DAPI)-containing PBS for
1min (dil. 1:20,000) and mounted with ProLong Diamond mounting
medium (cat. D1306 and cat. P36965, respectively, Thermo Fisher
Scientific). Cells were observed and photographed by confocal micro-
scopy (objective 40×) by using a Zeiss LSM 710 microscope (Carl Zeiss,
Thornwood, NY, USA) and Zen 2008 Software (Carl Zeiss Microscopy
GmbH, Jena, Germany). Digital images were analyzed by using an open
source Java-based Fiji-ImageJ image processing package, and the
coloc2 plug-in for colocalization. Results were given as Pearson coef-
ficients [30].
2.9. Serum sampling
Serum samples were obtained from female patients with clinical
diagnosis of typical RTT and MECP2 mutation (n=42; median age: 15)
and healthy controls (n= 16; median age: 16). As previously reported
[31], fasting venous blood was collected at 8–10 a.m. following an
overnight fast and all manipulations were carried out within 2 h. Blood
was collected in tubes without anticoagulants and allowed to clot at RT.
Following centrifugation at 1,500×g for 10min, the sera were trans-
ferred into clean tubes. Serum samples were stored at −80 °C for fur-
ther immunoblot (ASC and CASP1) or ELISA (IL-18) analyses.
2.10. ASC oligomerization assay
For the ASC oligomerization assay, five μl of serum were suspended
in 500 μL PBS and cross-linked with 2mM disuccinimidyl suberate
(DSS) for 30min a room temperature. Cross-linked samples were cen-
trifuged at 10,000×g for 15min at 4 °C. The pellets containing ASC
oligomers were boiled with 2x protein loading buffer for 5min for
Western blot analysis.
2.11. Enzyme-linked immunosorbent assay (ELISA)
Serum concentrations of IL-18 were determined by ELISA using a
commercial kit (RayBiotech Life, Peachtree Corners, GA, USA), ac-
cording to the manufacturer's instructions. All samples were analyzed in
duplicate. A calibration curve was performed using IL-18 as a standard.
The optical absorbance was measured with a microplate reader at
450 nm, and results are expressed as pg/mL. The lower limit of detec-
tion for IL-18 was 0.5 pg/mL.
2.12. Statistics
Statistical analyses were performed by using GraphPad Prism 6 and
Statsoft Statistica10 softwares. One-way or factorial ANOVA, with post-
hoc Tukey's tests were applied. The null hypothesis was rejected with P
less than 0.05. All data were expressed as means ± standard deviations
(SD).
3. Results
3.1. Constitutive nuclear translocation of NF-κB p65 and increased levels of
cleaved IL-1β in RTT fibroblasts
First critical step in inflammasome activation is the transcriptional
up-regulation of inflammasome components via nuclear factor (NF)-κB
signaling. As shown in Fig. 1A, RTT fibroblasts revealed highly aug-
mented levels of nuclear NF-κB p65 subunit in basal condition
(P < 0.01), as compared to unstimulated CTR. However, while CTR
fibroblasts responded to LPS + ATP treatment by increasing p65 nu-
clear translocation over time (after 2 and 6 h) (P < 0.05), p65 nuclear
levels did not increase any further after LPS + ATP in RTT fibroblasts
(Fig. 1A).
NF-κB–activating stimulus induces elevated expression of pro-IL-1β,
a key pro-inflammatory cytokine involved in the inflammasome
pathway [32]. RTT fibroblasts displayed a robust constitutive pro-IL-1β
mRNA expression in basal condition when compared to unstimulated
CTR cells (P < 0.05) (Fig. 1B). As expected, increased transcriptional
levels of pro-IL-1β have been detected in LPS + ATP-stimulated CTR
cells (P < 0.05; as compared to untreated CTR); whereas no further
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changes in pro-IL-1β levels were noticed in RTT fibroblasts after the
pro-inflammatory stimulation (Fig. 1B).
In line with these results, immunofluorescence analysis for the
cleaved IL-1β revealed an increase of green signal in cytoplasmic
compartment of untreated RTT cells as compared to basal CTR fibro-
blasts (Fig. 1C). No change in fluorescence intensity was observed in
RTT fibroblasts upon LPS + ATP stimulation when compared to the
unstimulated condition (Fig. 1C). On the other hand, an increased green
fluorescence for the mature IL-1β was evident in CTR fibroblasts after
LPS + ATP treatment (Fig. 1C).
3.2. NLRP3 inflammasome components are constitutively expressed at high
levels in RTT fibroblasts
In addition to NF-κB p65, other key players in the inflammasome
system were analyzed, including NLRP3 and ASC. Basal RTT fibroblasts
showed higher NLRP3 protein levels compared to CTR (P < 0.05),
without any evident change after pro-inflammatory stimulation
(Fig. 2A). Instead, NLRP3 levels in CTR fibroblasts were increased
significantly upon LPS + ATP treatment (P < 0.05; as compared to
untreated CTR) (Fig. 2A).
Similarly, an increase of ASC levels could be detected in basal RTT
Fig. 1. Constitutive nuclear translocation of NF-κB p65 and expression of cleaved IL-1β in RTT fibroblasts.
Panel A. Representative Western blots for NF-κB p65 in nuclear extracts from control and RTT fibroblasts stimulated with LPS 100 μg/ml for 2 and 6 h plus ATP 5mM
for 30min. Quantification is showed in bottom panel. Data are given as means ± SD. Panel B. The mRNA levels of pro-IL-1β were analyzed by real-time RT-PCR.
Data are expressed as 2−ΔΔCt, using GAPDH as the reference, and one of the controls as the internal calibrator. Data are given as means ± SD. Panel C.
Immunofluorescence for cleaved IL-1β in control and RTT fibroblasts stimulated with LPS 100 μg/ml for 6 h and ATP 5mM for 30min. Nuclei are stained with DAPI.
Bar= 15 μm. CTR, control; RTT, Rett syndrome; LPS, lipopolysaccharide; ATP, adenosine triphosphate. *P < 0.05; **P < 0.01. Results were analyzed by factorial
ANOVA (with 2 × 2 × 3 design for panel A, and 2 × 2 design for panel B), with post-hoc Tukey's multiple comparisons test.
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fibroblasts as compared to untreated CTR (P < 0.01), but with no
statistically significant variation in response to the pro-inflammatory
stimuli (Fig. 2B). On the other hand, in CTR cells ASC levels were low in
basal conditions, but significantly increased after LPS + ATP stimula-
tion (P < 0.05) (Fig. 2B).
3.3. RTT fibroblasts show an increased colocalization between NLRP3 and
ASC
To determine if high constitutive levels of the inflammasome com-
ponents in RTT cells paralleled with inflammasome assembly, we as-
sessed the NLRP3-ASC interaction by evaluating their cellular locali-
zation by immunofluorescence (Fig. 3).
In CTR cells, the LPS + ATP treatment induced an increase of the
NLRP3-related immunofluorescence signal into the cytoplasmic and
perinuclear region (likely, endoplasmic reticulum), as well as an en-
hanced ASC-related signal into the cytosol, as compared to un-
stimulated CTR cells (Fig. 3A). Conversely, in RTT fibroblasts, basal
signals of both NLRP3 and ASC are higher and localized in the cytosolic
compartment, whereas LPS + ATP stimulation did not affect the cy-
tosolic localization (Fig. 3A).
After co-localization analysis, we found that a significant NLRP3-
ASC interaction was induced by LPS + ATP only in CTR fibroblasts
(P < 0.05); while, RTT cells showed a significant increase of in-
flammasome assembly already in basal condition (P < 0.05; as com-
pared to untreated CTR), and were unable to respond to further chal-
lenge with LPS + ATP (Fig. 3B).
3.4. Altered levels of pro-CASP1 and active CASP1 form in RTT fibroblasts
The key outcome of NLRP3-ASC assembly is the self-cleavage and
activation of pro-CASP1 that, then, leads to the processing and ma-
turation of the pro-inflammatory cytokines IL-1β and IL-18 [12]. Given
the higher levels of cleaved IL-1β and inflammasome assembly in RTT
cells, we next evaluated the protein expression of the pro-form and
active form of CASP1.
In both basal and LPS + ATP stimulated conditions, RTT fibroblasts
displayed low pro-CASP1 levels respect to the CTR cells (P < 0.05)
(Fig. 4A). The basal levels of CASP1 p20 active form were similar be-
tween CTR and RTT cells, while the treatment with LPS + ATP in-
creased its levels in CTR cells (P < 0.05), no change was observed in
RTT fibroblasts after the pro-inflammatory stimulus (Fig. 4A).
To verify if regulation of pro-CASP1 protein expression occurs at the
transcription level, we assessed its mRNA expression by real time PCR.
As showed in Fig. 4B, in unstimulated conditions, RTT cells displayed a
trend in reduction of pro-CASP1 mRNA levels compared to CTR fibro-
blasts. After LPS + ATP stimulation, pro-CASP1 gene expression
showed a trend in increase in CTR cells, while no significant changes
were observed in RTT fibroblasts (Fig. 4B).
3.5. Increased release of inflammasome components in serum of RTT
patients
A growing body of evidence supports a model whereby the cellular
release of inflammasome proteins through extracellular vesicles such as
exosomes delivers their cargo in vivo to amplify the inflammatory sig-
naling in peripheral tissues [33,34]. Therefore, to further study in-
flammasome activation in RTT, we evaluated the protein expression of
the main inflammasome components in serum from RTT patients and
control subjects. Consistent with the results obtained in fibroblasts, we
found that ASC protein levels were higher in the serum of RTT patients
than in the control group (Fig. 5A). Furthermore, immunoblot analysis
of DSS-crosslinked ASC oligomers further confirmed a significant in-
crease of catalytically active ASC oligomeric species in RTT serum
samples (Fig. 5B). Next, as hallmark of inflammasome activation, we
measured the serum levels of IL-18 by ELISA. As showed in Fig. 5C,
serum IL-18 concentrations were significantly higher in RTT patients
than in control subjects (p < 0.05).
4. Discussion
The aim of our work was to elucidate the possible involvement of
the inflammasome pathway as a key player in RTT subclinical in-
flammation. Inflammasomes, cytoplasmic multi-protein complexes,
provide host immune defense against a diverse range of pathogen in-
fections and cellular stress signals [11]. As previously mentioned,
Fig. 2. Increased levels of NLRP3 and ASC in basal
RTT fibroblasts.
Panel A. Representative images and densitometric
analysis of Western blotting for NLRP3 in control
and RTT fibroblasts incubated without or with LPS
100 μg/ml for 6 h plus ATP 5mM. Panel B.
Representative images and densitometric analysis
of Western blots for ASC in control and RTT fi-
broblasts stimulated with LPS 100 μg/ml for 2 and
6 h plus ATP 5 mM. Data are given as
means ± SD. CTR, control; RTT, Rett syndrome;
LPS, lipopolysaccharide; ATP, adenosine tripho-
sphate. *P < 0.05; **P < 0.01. Results were
analyzed by Two-way ANOVA, with post-hoc
Tukey's multiple comparisons test.
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assembly of NLRP3/ASC inflammasome leads to subsequent recruit-
ment and autocatalytic activation of CASP1 that, finally, promotes the
maturation of IL-1β and IL-18 [11,35]. These key pro-inflammatory
cytokines are able to promote a multitude of finely regulated immune
responses useful for restoring the physiological conditions [11]. How-
ever, it is also well known that an uncontrolled and prolonged in-
flammasome activation with an excessive release of cytokines can
participate in the onset and progression of chronic inflammatory states
associated with a wide variety of human diseases [10,36,37].
Although RTT is primarily a genetic brain disorder with prominent
neurological symptoms, a vast body of evidence supports a key role for
the interplay between redox imbalance and a subclinical inflammatory
status (oxinflammation phenomenon) in different systemic abnormal-
ities observed in RTT patients (i.e., mitochondrial dysfunctions, meta-
bolic alterations, immune dysregulation, gastrointestinal problems,
breathing disturbances and recurrent infections) [6,38]. In this contest,
the dysregulation of NLRP3 inflammasome pathway could be a new
molecular mechanism able to contribute to RTT pathophysiology, in
both brain and periphery.
In general, although still under debate [39], it is accepted that the
molecular mechanisms leading to the inflammasome activation are
mainly driven by two different signals. Typically, ‘signal 1’ or ‘priming’
molecules (e.g., LPS) induce the expression of NLRP3, pro-IL-1β and
pro-IL-18 via NF-κB activation [32,39]. Moreover, PAMPs or DAMPs
(e.g., ATP, particulate matter, heme, pathogen-associated RNA, etc)
activate the NLRP3 inflammasome assembly (‘signal 2’) [32]. The
particular interest towards NLRP3 inflammasome lies in the broad
range of molecular and cellular signaling events that are induced by its
activators among which there are ionic flux (e.g., K+, Na+, chloride
fluxes and Ca2+ signaling), ROS production, lysosomal destabilization,
mitochondrial dysfunction and post-translational modifications of
NLRP3 [40,41]. Of note, some of these stimuli are present in RTT pa-
tients [42,43] and, therefore, could promote a dysregulated NLRP3
inflammasome function that, in turn, could contribute to the typical
RTT subclinical inflammation [6,38,44].
In the present work, RTT cells showed an increased steady level of
nuclear NF-κB p65 subunit, as compared to CTR cells. A significant
increase of NF-κB p65 nuclear translocation was found in CTR cells after
LPS + ATP treatment, whereas RTT fibroblasts did not undergo any
significant change in the transcription factor nuclear levels in response
to the inflammatory stimuli. These peculiar results suggest that, in basal
conditions, RTT fibroblasts exhibit a marked NF-κB p65 activation
Fig. 3. Increased formation of NLRP3/ASC in-
flammasome complexes in RTT fibroblasts.
Panel A. Confocal images showing localization of
NLRP3 (green fluorescence) and ASC (red fluor-
escence) in control and RTT fibroblasts stimulated
with LPS 100 μg/ml for 6 h and ATP 5mM for
30min. Overlay of the green and red channel
shows that there is colocalization between NLRP3
and ASC. Nuclei are stained with DAPI.
Bar= 15 μm. CTR, control; RTT, Rett syndrome;
LPS, lipopolysaccharide; ATP, adenosine tripho-
sphate. *P < 0.05. Panel B. Pearson's correlation
coefficient values for colocalization of NLRP3 and
ASC. Co-localization data were given as
means ± SD. Results were analyzed by Two-way
ANOVA, with post-hoc Tukey's multiple compar-
isons test. (For interpretation of the references to
colour in this figure legend, the reader is referred
to the Web version of this article.)
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which amplitude cannot be achieved by control cells even upon pro-
inflammatory stimulation. This indicates the occurrence of an already
activated inflammatory response in RTT fibroblasts that, on the other
hand, seem unable to respond to further pro-inflammatory challenges.
Our results on the constitutively activated status of NF-κB p65 sig-
naling with the subsequent increased levels of IL-1β; production of
which is induced only in response to inflammatory stimuli [45], may be
likely related to the oxinflammation condition typical of RTT [6,38].
Indeed, multiple elements support the implication of a chronic, low-
grade inflammation in RTT, including high levels of inflammatory
markers and deregulation of acute phase response (APR) proteins, an
unbalanced plasma cytokines profile coupled with an abnormal
morphology of peripheral blood mononuclear cells (PBMCs) [6].
Moreover, we recently demonstrated an increased gene expression of
arachidonate 15-lipoxygenase (ALOX15) in RTT PBMC [44]. This en-
zyme is able to oxidize polyunsaturated fatty acids such as linoleic acid,
producing 13- and 9- hydroxyoctadecadienoic acid (13-HODE and 9-
HODE, respectively); levels of these two compounds were found also
increased in RTT serum [44]. High HODEs levels are able to exert pro-
inflammatory effects such as the induction of cytokines and cell adhe-
sion molecules expression, the modulation of immune cells chemotaxis
and monocyte adhesion to vascular endothelial cells and the activation
of transcription factors including NF-κB [46]. In addition, beyond the
subclinical inflammation, also the redox imbalance, widely observed in
RTT, could be another plausible mechanism able to induce the up-
regulation of redox-sensitive transcriptional factors such as NF-κB [47].
Of note, an aberrant NF-κB signaling has been already reported in RTT
and related to MECP2 deficiency, in both patients and animal models.
Alterations of the NF-kB pathway were first revealed in a transcrip-
tional profiling study on the whole blood of RTT patients [48]. Then,
the possible involvement of MECP2 in immune function regulation was
suggested by the enhanced NF-κB signaling coupled with an increased
expression of inflammatory cytokines (i.e., TNFα, IL-6, and IL-3) found
in MECP2-deficient human PBMCs and in the human monocyte line
THP1 [49,50]. In line with these works, microglia and macrophages
from Mecp2-deficient mice displayed a deregulated inflammatory re-
sponse with an abnormal transcriptional expression of inflammatory
genes after TNFα stimulation [51]. A study by Kishi and colleagues [52]
on the cortex of Mecp2-null mice demonstrated an abnormal upregu-
lation of NF-κB signaling, which reduction ameliorated the dendritic
complexity of callosal projection neurons and prolonged their normal
lifespan. Similarly, a marked decrease in inflammation markers was
observed in the cerebellar area of Mecp2-knockout mice after treatment
with a specific glycogen synthase kinase-3b (Gsk3b) inhibitor that at-
tenuated the nuclear NF-κB activity [53]. Together, these evidence and
our results suggest the hypothesis that NF-κB pathway dysregulation
could play a significant role in RTT pathophysiology, as already proven
in rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis,
atherosclerosis, systemic lupus erythematosus, type I diabetes, chronic
obstructive pulmonary disease and asthma [54].
In addition to regulate multiple aspects of the immune and in-
flammatory functions, NF-κB also has a role in regulating the activation
of inflammasomes by inducing the transcriptional expression of NLRP3,
pro-IL-1β and pro-IL-18 [32,39]. Therefore, based on the evidence of a
constitutive activation of NF-κB p65 in RTT fibroblasts, we continued
our study by analyzing the main components of NLRP3 signaling
pathway. In order to achieve an effective inflammasome-mediated re-
sponse, the presence of the adaptor protein ASC is crucial, since it can
recruit the pro-caspase-1 through a “caspase activation and recruitment
domain” (CARD), facilitating caspase-1 dimerization and activation,
thus ensuring the formation of a fully functional inflammasome [55].
About ASC, as expected, LPS + ATP increased markedly the levels of
ASC in CTR cells, whereas, although exhibiting significantly higher
basal levels of ASC, as compared to CTR fibroblasts, RTT cells did not
undergo any change upon LPS/ATP treatment. Several papers showed
that ASC gene is under the control of a methylation-sensitive promoter
[56,57]. In addition, Webb and colleagues [58], by using an IRIDESC-
ENT algorithm analysis, revealed that ASC is sensitive to MECP2 ac-
tivity and, moreover, transcriptional silencing of ASC gene, associated
with the complete methylation of its promoter region, was observed in
prostate cancer [59]. Therefore, we hypothesize that the loss of the
transcriptional repression activity by a deficient MECP2 could be a
mechanism able to explain the increase of ASC levels in RTT fibroblasts
[60]. Furthermore, the increased basal levels of ASC in RTT fibroblasts
could also be another hypothetic molecular mechanism able to explain
the constitutive NF-κB p65 hyperactivation. Indeed, there is evidence
that identified ASC as an upstream regulator of NF-κB signaling [61].
Since NLRP3 protein expression in RTT fibroblasts was found to be
Fig. 4. Altered protein and mRNA levels of caspase 1 in RTT fibroblasts.
Panel A. Representative Western blots images for pro-CASP1 and active CASP1
p20 in control and RTT fibroblasts stimulated with LPS 100 μg/ml for 6 h and
ATP 5 mM for 30 min. Quantification is showed in bottom panel. Data were
given as means ± SD. CTR, control; RTT, Rett syndrome; LPS, lipopoly-
saccharide; ATP, adenosine triphosphate. *P < 0.05. Results were analyzed by
Two-way ANOVA, with post-hoc Tukey's multiple comparisons test. Panel B.
The mRNA levels of pro-CASP1 were analyzed by real-time RT-PCR. Data are
expressed as 2−ΔΔCt, using GAPDH as the reference, and one of the controls as
the internal calibrator. Data are given as means ± SD. CTR, control; RTT, Rett
syndrome; LPS, lipopolysaccharide; ATP, adenosine triphosphate. *P < 0.05.
Results were analyzed by Two-way ANOVA, with post-hoc Tukey's multiple
comparisons test.
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substantially unchanged after LPS + ATP treatment, we performed a
multiple immunofluorescence-based analysis of NLRP3 and ASC, in
order to estimate the interaction between these proteins to determine
the inflammasome assembly process [20]. Our results provided evi-
dence of an increased interaction between NLRP3 and ASC in un-
stimulated RTT cells. Furthermore, as expected, control fibroblasts
showed increased NLRP3/ASC co-distribution, following the pro-in-
flammatory challenge, whereas RTT cells were unable to display a si-
milar behavior. Such results are consistent with the data related to NF-
κB p65 signaling and cytosolic ASC levels discussed above. The pre-
activated status of NLRP3/ASC inflammasome could be also linked to
the redox imbalance and the mitochondrial dysfunction, aspects re-
peatedly described in RTT [42]. Indeed, mitochondrial events have
been associated with NLRP3 activation in several different pathological
conditions [62]. By acting upstream of the NLRP3 activation, mi-
tochondria can provide ROS to induce NLRP3 oligomerization and be a
platform for inflammasome assembly [63,64]. Interestingly, recent
findings also revealed a role for HODEs, that we found increased in RTT
serum [44], as positive modulators of NLRP3 inflammasome assembly
and caspase-1 activation [65].
In addition, the LPS + ATP treatment enhanced the levels of the
cleaved form of caspase-1 (p20) in CTR cells, in coherence with the
increased co-localization of the sensor NLRP3 and the adaptor ASC
proteins within the cytoplasm, thus confirming that the LPS + ATP
promoted the functional assembly of inflammasome in fibroblasts from
healthy individuals. In basal condition, RTT cells were found to have
unchanged levels of CASP1 p20. However, the basal activation state of
the CASP1 seemed to be higher in RTT fibroblasts than in CTR cells, as
shown by the markedly lower pro-CASP1 protein levels found in fi-
broblasts from RTT patients. This idea was confirmed by the fact that
RTT cells did not undergo any statistically significant change of CASP1
p20 protein level upon pro-inflammatory stimulus. In addition, since
images on cleaved IL-1β showed an increased green signal in un-treated
RTT fibroblasts, similar to the fluorescence intensity of LPS plus ATP
stimulated CTR fibroblasts, we can suppose that CASP1 is able to
properly work in the cleavage and maturation of IL-1β. While this
finding requires further investigations, a plausible explanation for the
levels of CASP1 (pro-form and mature form) observed in RTT could be
found in an enhanced extracellular release trough extracellular vesicles
like exosomes [33,34]. Indeed, in addition to NLRP3 and ASC specks
[66,67], also caspase-1 is found in extracellular vesicles. Moreover,
recent papers revealed that pro-caspase-1 could be also activated in
extracellular compartments, leading to the subsequent cleavage of its
substrates in exocytotic secretory pathways, such as exosomes, to dis-
seminate the inflammatory signals to adjacent cells and tissues [68].
Based on the evidence of the extracellular release of inflammasome
components and a recent report that showed increased concentrations
of caspase-1, IL-1β and IL-18 in serum samples from ASD patients [22]
(clinically similar to RTT), we decided to confirm our in vitro results on
RTT fibroblasts also in the serum from RTT patients. The increased
serum levels of ASC oligomers and IL-18 corroborated our cellular
findings on the occurrence of a deregulated inflammasome pathway in
RTT. Indeed, there is evidence that ASC oligomers remain catalytically
active in circulation and, after phagocytosis by adjacent cells, can
propagate inflammasome activation, thereby augmenting the pro-in-
flammatory cascade [67].
Therefore, taken together our data suggest that de-regulated in-
flammasome activation may have a role in the occurrence of a sub-
clinical inflammatory status in RTT. Several findings demonstrated that
a low-grade inflammatory response, avoiding a negative feedback reg-
ulation, together with the presence of ROS during the inflammatory
processes play a key role in several pathologies: genetic diseases
[11,69], diabetes [70], cardiovascular disease [71], cancer [72], and
neurodegenerative disorders, such as Alzheimer's and Parkinson's dis-
ease [73]. Some of these pathologies have been associated to in-
flammasome de-regulated activation [21,32].
In addition, several authors demonstrated that ROS production, via
the NAD(P)H-oxidase (NOX) activity, induces the formation and acti-
vation of NLRP3 inflammasome in different in vitro and in vivo models
[74,75]. Cervellati and co-workers [7] demonstrated that RTT fibro-
blasts exhibited high NOX enzymatic activity, together with increased
levels of superoxide anion and hydrogen peroxide. Hence, the reported
Fig. 5. Increased release of inflammasome components in serum of RTT patients.
Panel A. Representative Western blots images for ASC in serum samples from control subjects and RTT patients. Quantification is showed in right panel. Panel B.
Representative images and densitometric analysis of Western blotting for ASC oligomers in serum samples from control subjects and RTT patients. Quantification is
showed in bottom panel. Panel C. Serum levels of IL-18 in control subjects and RTT patients were quantified by ELISA. For all the panels, the results are presented as
means ± SD. CTR, control; RTT, Rett syndrome; *P < 0.05. Results were analyzed by t-test for independent groups (CTR N=17; RTT N=41).
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inflammasome activation in RTT may be likely due also to a NOX-de-
pendent response.
Our experiments show that RTT fibroblasts were unable to activate
an inflammasome-dependent response to pro-inflammatory stimuli,
since they exhibited an already altered machinery, thus suggesting a
role of inflammasome in the subclinical inflammatory status, char-
acterizing the pathology (Scheme 1) [6,38]. It is known that stimulation
of the immune system in response to sterile insults can lead to chronic
debilitating conditions. Hence, for insulted cells it is crucial to co-
ordinate the recognition, initiation, and elaboration of signals inducing
inflammasome response, in order to promote the resolution. Whereas a
dysregulation of this system can result in disease [14].
5. Conclusions
In conclusion, we report that, along with oxidative stress and mi-
tochondrial dysfunction, a state of constitutive activation of the in-
flammasome system occurs in RTT, which, in turn, may feed and
perpetuate the subclinical inflammatory condition observed in this
disease.
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